KZR
Kezar Life Sciences, Inc.
Biotechnology
Market Cap$54M
5Y Perf.-98.6%
Build Your Comparison
Side-by-side financial analysisKZR
PRAX
Try popular comparisons:
Stock Comparison
KZR vs PRAX
Revenue, margins, valuation, and 5-year total return — side by side.
PRAX
Praxis Precision Medicines, Inc.
Biotechnology
Market Cap$7.70B
5Y Perf.-39.3%
KZR vs PRAX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  KZR |  PRAX |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $54M | $7.70B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-45M | $-327M |
| Total Debt | $2M | $110K |
| Cash & Equiv. | $72M | $357M |
KZR vs PRAX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
KZR
PRAX
| Stock | Oct 20 | May 26 | Return |
|---|---|---|---|
| Kezar Life Sciences… (KZR) | 100 | 1.4 | -98.6% |
| Praxis Precision Me… (PRAX) | 100 | 60.7 | -39.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KZR vs PRAX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: KZR leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Praxis Precision Medicines, Inc. is the stronger pick specifically for recent price momentum and sentiment and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
🥇KZR emerged as the overall leader. Track its performance:
KZR
Kezar Life Sciences, Inc.
The Income Pick
KZR carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 0.72
- Lower volatility, beta 0.72, Low D/E 3.3%, current ratio 11.52x
- Beta 0.72, current ratio 11.52x
Best for: income & stability and sleep-well-at-night
PRAX
Praxis Precision Medicines, Inc.
The Growth Play
PRAX is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth -100.0%, EPS growth -32.0%
- -36.1% 10Y total return vs KZR's -99.6%
- +491.9% vs KZR's +52.2%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  KZR | 42.6% revenue growth vs PRAX's -100.0% |
| Quality / Margins | KZR | 5.8% margin vs PRAX's 2.4% |
| Stability / Safety | KZR | Beta 0.72 vs PRAX's 1.55 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) |  PRAX | +491.9% vs KZR's +52.2% |
| Efficiency (ROA) | PRAX | -40.2% ROA vs KZR's -51.5%, ROIC -65.0% vs -85.3% |
KZR vs PRAX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
KZR vs PRAX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLKZRLAGGINGPRAX
PRAXPraxis Precision Medi…
2leads
KZRKezar Life Sciences, …
2leads
6 Total Categories
CATEGORYLEADERvs PRAXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
KZR1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
PRAX7/8
Total Returns1Y, 3Y, 5Y total returns with dividends
PRAX5/6
Risk & VolatilityBeta, volatility, and downside exposure
KZR2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
KZR leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
KZR and PRAX operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | KZRKezar Life Scienc… | PRAXPraxis Precision … |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$41M | -$357M |
| Net IncomeAfter-tax profit | -$45M | -$327M |
| Free Cash FlowCash after capex | -$42M | -$283M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +65.6% | +2.7% |
KZR leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — KZR and PRAX each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | KZRKezar Life Scienc… | PRAXPraxis Precision … |
|---|---|---|
| Market CapShares × price | $54M | $7.7B |
| Enterprise ValueMkt cap + debt − cash | -$16M | $7.3B |
| Trailing P/EPrice ÷ TTM EPS | -0.95x | -19.77x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 0.76x | 6.83x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — KZR and PRAX each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
PRAX leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
PRAX delivers a -43.0% return on equity — every $100 of shareholder capital generates $-43 in annual profit, vs $-58 for KZR. PRAX carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to KZR's 0.03x. On the Piotroski fundamental quality scale (0–9), KZR scores 4/9 vs PRAX's 3/9, reflecting mixed financial health.
| Metric | KZRKezar Life Scienc… | PRAXPraxis Precision … |
|---|---|---|
| ROE (TTM)Return on equity | -58.4% | -43.0% |
| ROA (TTM)Return on assets | -51.5% | -40.2% |
| ROICReturn on invested capital | -85.3% | -65.0% |
| ROCEReturn on capital employed | -53.8% | -49.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 |
| Debt / EquityFinancial leverage | 0.03x | 0.00x |
| Net DebtTotal debt minus cash | -$70M | -$357M |
| Cash & Equiv.Liquid assets | $72M | $357M |
| Total DebtShort + long-term debt | $2M | $110,000 |
| Interest CoverageEBIT ÷ Interest expense | -38.59x | — |
PRAX leads this category, winning 7 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
PRAX leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PRAX five years ago would be worth $8,580 today (with dividends reinvested), compared to $126 for KZR. Over the past 12 months, PRAX leads with a +491.9% total return vs KZR's +52.2%. The 3-year compound annual growth rate (CAGR) favors PRAX at 164.8% vs KZR's -69.0% — a key indicator of consistent wealth creation.
| Metric | KZRKezar Life Scienc… | PRAXPraxis Precision … |
|---|---|---|
| YTD ReturnYear-to-date | +15.9% | -6.9% |
| 1-Year ReturnPast 12 months | +52.2% | +491.9% |
| 3-Year ReturnCumulative with dividends | -97.0% | +1757.4% |
| 5-Year ReturnCumulative with dividends | -98.7% | -14.2% |
| 10-Year ReturnCumulative with dividends | -99.6% | -36.1% |
| CAGR (3Y)Annualised 3-year return | -69.0% | +164.8% |
PRAX leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
KZR leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
KZR is the less volatile stock with a 0.72 beta — it tends to amplify market swings less than PRAX's 1.55 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KZR currently trades 96.6% from its 52-week high vs PRAX's 72.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KZRKezar Life Scienc… | PRAXPraxis Precision … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.72x | 1.55x |
| 52-Week HighHighest price in past year | $7.55 | $366.52 |
| 52-Week LowLowest price in past year | $3.53 | $37.19 |
| % of 52W HighCurrent price vs 52-week peak | +96.6% | +72.7% |
| RSI (14)Momentum oscillator 0–100 | 52.4 | 31.9 |
| Avg Volume (50D)Average daily shares traded | 111K | 396K |
KZR leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates KZR as "Hold" and PRAX as "Buy". Consensus price targets imply 127.8% upside for PRAX (target: $607) vs -17.7% for KZR (target: $6).
| Metric | KZRKezar Life Scienc… | PRAXPraxis Precision … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $6.00 | $607.15 |
| # AnalystsCovering analysts | 7 | 16 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
KZR leads in 2 of 6 categories (Income & Cash Flow, Risk & Volatility). PRAX leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.
Best OverallKezar Life Sciences, Inc. (KZR)Leads 2 of 6 categories
Loading custom metrics...
KZR vs PRAX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is KZR or PRAX a better buy right now?
Analysts rate Praxis Precision Medicines, Inc.
(PRAX) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — KZR or PRAX?
Over the past 5 years, Praxis Precision Medicines, Inc.
(PRAX) delivered a total return of -14. 2%, compared to -98. 7% for Kezar Life Sciences, Inc. (KZR). Over 10 years, the gap is even starker: PRAX returned -36. 1% versus KZR's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — KZR or PRAX?
By beta (market sensitivity over 5 years), Kezar Life Sciences, Inc.
(KZR) is the lower-risk stock at 0. 72β versus Praxis Precision Medicines, Inc. 's 1. 55β — meaning PRAX is approximately 116% more volatile than KZR relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 3% for Kezar Life Sciences, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — KZR or PRAX?
On earnings-per-share growth, the picture is similar: Praxis Precision Medicines, Inc.
grew EPS -32. 0% year-over-year, compared to -566. 1% for Kezar Life Sciences, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — KZR or PRAX?
Kezar Life Sciences, Inc.
(KZR) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Praxis Precision Medicines, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KZR leads at 0. 0% versus 0. 0% for PRAX. At the gross margin level — before operating expenses — KZR leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — KZR or PRAX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is KZR or PRAX better for a retirement portfolio?
For long-horizon retirement investors, Kezar Life Sciences, Inc.
(KZR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 72)). Praxis Precision Medicines, Inc. (PRAX) carries a higher beta of 1. 55 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KZR: -99. 6%, PRAX: -36. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between KZR and PRAX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.